Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 294 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Bolus Clear all
Terminated Phase 2 Interventional Results available

KL₄Surfactant Treatment in Patients With ARDS

NCT00215553
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
A.1 Lucinactant, B.3 SoC, A.2 Lucinactant, A.3 Lucinactant, A.4 Lucinactant, B.1 Lucinactant, B.2 Lucinactant
Drug · Other
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
16 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 28, 2026, 3:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery

NCT01986751
View directory record Official record
Conditions
Pain
Interventions
Clonidine, ropivacaine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

NCT00157157
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 6 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789
View directory record Official record
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 28, 2026, 3:32 AM EDT
Active, not recruiting Phase 1 Interventional

Precision Antibiotic Dosing for Appendectomy

NCT06860802
View directory record Official record
Conditions
Appendicitis (Diagnosis)
Interventions
Cefoxitin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

NCT04662710
View directory record Official record
Conditions
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Interventions
Pembrolizumab, Lenvatinib, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Recruiting Phase 3 Interventional

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

NCT06998940
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
274
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Suspended Phase 1Phase 2 Interventional

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589
View directory record Official record
Conditions
Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions
Azeliragon, Stereotactic radiosurgery, Corticosteroid
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

NCT02283268
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand Factor (rVWF)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Miami, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Results available

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

NCT02657031
View directory record Official record
Conditions
Headache
Interventions
Prochlorperazine, Ketamine, Diphenhydramine, Ondansetron, Normal Saline
Drug
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition

NCT01141972
View directory record Official record
Conditions
Hot Flushes, Menopause, Premature, Obesity, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 28, 2026, 3:32 AM EDT
Not yet recruiting Phase 2 Interventional

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

NCT07635524
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cu-NU101
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Newport Beach, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Active, not recruiting Phase 2 Interventional

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

NCT00338377
View directory record Official record
Conditions
Melanoma
Interventions
Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Recruiting Phase 1 Interventional

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

NCT05901545
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Panitumumab, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Surgical Procedure, Imaging agent, Intraoperative Imaging, Near Infrared Imaging, Electrocardiography, Biospecimen Collection
Biological · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Completed No phase listed Observational

F18-MHF: Implants-Associated Infection Detection

NCT05889286
View directory record Official record
Conditions
Knee Disease, Knee Infection
Interventions
[F-18]MHF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Recruiting No phase listed Observational

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

NCT04489719
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
Procedure · Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder

NCT02992899
View directory record Official record
Conditions
PostTraumatic Stress Disorder
Interventions
GammaCore/electroCore non-invasive VNS device, Sham gammaCore/electroCore, O-15 water
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 28, 2026, 3:32 AM EDT
Recruiting Phase 3 Interventional

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
132
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Safety of Intravenous Thrombolytics in Stroke on Awakening

NCT01643902
View directory record Official record
Conditions
Stroke
Interventions
tPA
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 28, 2026, 3:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

NCT02447874
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Arginine, Arginine (Loading), Arginine (Continuous)
Drug
Lead sponsor
Emory University
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Safety of Intravenous Thrombolysis for Wake-up Stroke

NCT01183533
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Alteplase (iv t-PA)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Englewood, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 28, 2026, 3:32 AM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

NCT06205485
View directory record Official record
Conditions
Rectal Cancer
Interventions
Leucovorin, Oxaliplatin, Fluoruracil, Capecitabine, Radiation
Drug · Radiation
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
105
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

NCT01749956
View directory record Official record
Conditions
Rectal Cancer
Interventions
Radiation, Aflibercept, Surgery, FOLFOX6
Radiation · Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Fort Myers, Florida • Pensacola, Florida • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 28, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT05785832
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 3:32 AM EDT